Form 4: Acrivon Therapeutics Director Granted Stock Options in Routine Compensation Filing

Ivana Magovcevic-Liebisch, a Director at Acrivon Therapeutics, Inc., was granted 20,275 stock options with an exercise price of $1.20 per share, as detailed in a recent SEC Form 4 filing.

Summary

• Ivana Magovcevic-Liebisch, a Director of Acrivon Therapeutics, Inc. (ACRV), acquired 20,275 stock options on June 13, 2025.
• The stock options have an exercise price of $1.20 per share.
• The options were granted at a price of $0, indicating they are part of a compensation package.
• These options will expire on June 12, 2035.
• The shares subject to the option will vest on the date immediately preceding the Issuer's next annual meeting of stockholders, contingent on Ms. Magovcevic-Liebisch's continuous service.
• Following this transaction, Ms. Magovcevic-Liebisch directly beneficially owns 20,275 derivative securities.
• The filing also includes a Power of Attorney dated May 16, 2025, authorizing certain individuals to execute and file SEC forms on behalf of Ms. Magovcevic-Liebisch.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive, as it represents a standard compensation event for a director, aligning their interests with the company's performance without indicating any immediate operational or financial changes.

Positives

• The grant of stock options aligns the interests of the director, Ivana Magovcevic-Liebisch, with those of the shareholders, as the options gain value if the company's stock price increases.
• This is a standard form of compensation for directors, indicating ongoing commitment and incentivization.

Future Outlook

The stock options are subject to vesting on the date immediately preceding the Issuer's next annual meeting of stockholders, contingent upon the director's continuous service.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically the grant of equity compensation to a director. Such grants are common practice across various industries, including biotechnology, to align the interests of leadership with long-term shareholder value.

Related Party Transactions

• The grant of 20,275 stock options to Ivana Magovcevic-Liebisch, a Director, constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor future dilution if exercised, but primarily serves to align the director's interests with shareholder value creation.
• Director (Ivana Magovcevic-Liebisch): Receives equity compensation, incentivizing long-term commitment and performance.

Next Steps

• The stock options will vest on the date immediately preceding the Issuer's next annual meeting of stockholders, provided the director maintains continuous service.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, Stock Option Grant, Director Compensation, Insider Transaction, Equity Compensation, SEC Filing